Switch to:
Also traded in: Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.05
BDX's Cash-to-Debt is ranked lower than
96% of the 201 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.57 vs. BDX: 0.05 )
Ranked among companies with meaningful Cash-to-Debt only.
BDX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 0.19 Max: 1.03
Current: 0.05
0.03
1.03
Equity-to-Asset 0.38
BDX's Equity-to-Asset is ranked lower than
81% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. BDX: 0.38 )
Ranked among companies with meaningful Equity-to-Asset only.
BDX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.25  Med: 0.47 Max: 0.63
Current: 0.38
0.25
0.63
Debt-to-Equity 1.07
BDX's Debt-to-Equity is ranked lower than
86% of the 147 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.36 vs. BDX: 1.07 )
Ranked among companies with meaningful Debt-to-Equity only.
BDX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.23  Med: 0.61 Max: 2
Current: 1.07
0.23
2
Debt-to-EBITDA 10.90
BDX's Debt-to-EBITDA is ranked lower than
94% of the 107 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.91 vs. BDX: 10.90 )
Ranked among companies with meaningful Debt-to-EBITDA only.
BDX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.56  Med: 1.88 Max: 7.3
Current: 10.9
0.56
7.3
Interest Coverage 1.53
BDX's Interest Coverage is ranked lower than
93% of the 137 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 63.92 vs. BDX: 1.53 )
Ranked among companies with meaningful Interest Coverage only.
BDX' s Interest Coverage Range Over the Past 10 Years
Min: 2.84  Med: 11.72 Max: 42.29
Current: 1.53
2.84
42.29
Piotroski F-Score: 6
Altman Z-Score: 1.69
Beneish M-Score: -2.21
WACC vs ROIC
8.18%
2.20%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 7.31
BDX's Operating Margin % is ranked higher than
57% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.16 vs. BDX: 7.31 )
Ranked among companies with meaningful Operating Margin % only.
BDX' s Operating Margin % Range Over the Past 10 Years
Min: 10.45  Med: 19.61 Max: 22.75
Current: 7.31
10.45
22.75
Net Margin % 3.29
BDX's Net Margin % is ranked lower than
52% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.70 vs. BDX: 3.29 )
Ranked among companies with meaningful Net Margin % only.
BDX' s Net Margin % Range Over the Past 10 Years
Min: 6.76  Med: 15.56 Max: 18.49
Current: 3.29
6.76
18.49
ROE % 2.36
BDX's ROE % is ranked lower than
55% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.98 vs. BDX: 2.36 )
Ranked among companies with meaningful ROE % only.
BDX' s ROE % Range Over the Past 10 Years
Min: 10.01  Med: 24.34 Max: 28.17
Current: 2.36
10.01
28.17
ROA % 1.13
BDX's ROA % is ranked lower than
54% of the 203 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.85 vs. BDX: 1.13 )
Ranked among companies with meaningful ROA % only.
BDX' s ROA % Range Over the Past 10 Years
Min: 3.47  Med: 10.87 Max: 14.79
Current: 1.13
3.47
14.79
ROC (Joel Greenblatt) % 16.52
BDX's ROC (Joel Greenblatt) % is ranked higher than
59% of the 201 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.73 vs. BDX: 16.52 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BDX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 21.71  Med: 33.7 Max: 40.37
Current: 16.52
21.71
40.37
3-Year Revenue Growth Rate 8.20
BDX's 3-Year Revenue Growth Rate is ranked higher than
65% of the 162 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. BDX: 8.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BDX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 4.4  Med: 8.4 Max: 12.4
Current: 8.2
4.4
12.4
3-Year EBITDA Growth Rate 1.00
BDX's 3-Year EBITDA Growth Rate is ranked lower than
64% of the 149 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.20 vs. BDX: 1.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BDX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -11  Med: 8.2 Max: 32.2
Current: 1
-11
32.2
3-Year EPS without NRI Growth Rate -8.40
BDX's 3-Year EPS without NRI Growth Rate is ranked lower than
70% of the 147 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.00 vs. BDX: -8.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
BDX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -14.2  Med: 9.1 Max: 21.9
Current: -8.4
-14.2
21.9
GuruFocus has detected 5 Warning Signs with Becton, Dickinson and Co BDX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BDX's 30-Y Financials

Financials (Next Earnings Date: 2018-05-04)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2017

BDX Guru Trades in Q1 2017

Steven Cohen 556,000 sh (New)
Caxton Associates 3,400 sh (New)
Pioneer Investments 282,637 sh (+6.40%)
T Rowe Price Equity Income Fund 1,009,000 sh (+2.54%)
Robert Olstein 36,100 sh (unchged)
Tom Gayner 9,000 sh (unchged)
Jim Simons Sold Out
Louis Moore Bacon Sold Out
Mario Gabelli 116,356 sh (-1.88%)
Mairs and Power 4,640 sh (-2.89%)
Jeff Auxier 25,225 sh (-3.81%)
Vanguard Health Care Fund 992,573 sh (-4.77%)
Ken Fisher 1,659 sh (-5.74%)
Jeremy Grantham 597,795 sh (-21.81%)
Dodge & Cox 8,830 sh (-36.15%)
Ray Dalio 3,100 sh (-89.50%)
» More
Q2 2017

BDX Guru Trades in Q2 2017

Joel Greenblatt 13,416 sh (New)
Vanguard Health Care Fund 1,522,573 sh (+53.40%)
Ken Fisher 1,984 sh (+19.59%)
Caxton Associates 3,800 sh (+11.76%)
Jeremy Grantham 606,340 sh (+1.43%)
Tom Gayner 9,000 sh (unchged)
Jeff Auxier 25,225 sh (unchged)
Ray Dalio Sold Out
Steven Cohen Sold Out
Mairs and Power 4,356 sh (-6.12%)
T Rowe Price Equity Income Fund 938,800 sh (-6.96%)
Dodge & Cox 7,780 sh (-11.89%)
Mario Gabelli 100,076 sh (-13.99%)
Pioneer Investments 234,216 sh (-17.13%)
Robert Olstein 27,100 sh (-24.93%)
» More
Q3 2017

BDX Guru Trades in Q3 2017

Ray Dalio 19,207 sh (New)
Jim Simons 160,551 sh (New)
Paul Tudor Jones 18,339 sh (New)
Joel Greenblatt 42,133 sh (+214.05%)
Ken Fisher 2,340 sh (+17.94%)
Tom Gayner 9,000 sh (unchged)
Vanguard Health Care Fund 1,522,573 sh (unchged)
Jeff Auxier 25,225 sh (unchged)
Mairs and Power 4,356 sh (unchged)
Dodge & Cox 7,730 sh (-0.64%)
Robert Olstein 26,600 sh (-1.85%)
Caxton Associates 3,600 sh (-5.26%)
T Rowe Price Equity Income Fund 840,000 sh (-10.52%)
Jeremy Grantham 541,066 sh (-10.77%)
Pioneer Investments 129,424 sh (-44.74%)
Mario Gabelli 47,316 sh (-52.72%)
» More
Q4 2017

BDX Guru Trades in Q4 2017

Lee Ainslie 10,223 sh (New)
George Soros 2,100 sh (New)
Jim Simons 2,074,503 sh (+1192.11%)
Pioneer Investments 559,551 sh (+332.34%)
Caxton Associates 6,431 sh (+78.64%)
Robert Olstein 27,000 sh (+1.50%)
Ken Fisher 2,362 sh (+0.94%)
Tom Gayner 9,000 sh (unchged)
Vanguard Health Care Fund Sold Out
Ray Dalio Sold Out
Jeff Auxier 25,175 sh (-0.20%)
Mairs and Power 4,317 sh (-0.90%)
Jeremy Grantham 532,868 sh (-1.52%)
T Rowe Price Equity Income Fund 790,000 sh (-5.95%)
Dodge & Cox 7,130 sh (-7.76%)
Mario Gabelli 38,702 sh (-18.21%)
Paul Tudor Jones 6,124 sh (-66.61%)
Joel Greenblatt 1,835 sh (-95.64%)
» More
» Details

Insider Trades

Latest Guru Trades with BDX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
T Rowe Price Equity Income Fund 2017-12-31 Reduce -5.95%0.05%$193.73 - $227.15 $ 220.343%790,000
Mario Gabelli 2017-12-31 Reduce -18.21%0.01%$193.73 - $227.15 $ 220.343%38,702
Robert Olstein 2017-12-31 Add 1.50%0.01%$193.73 - $227.15 $ 220.343%27,000
Dodge & Cox 2017-12-31 Reduce -7.76%$193.73 - $227.15 $ 220.343%7,130
Ken Fisher 2017-12-31 Add 0.94%$193.73 - $227.15 $ 220.343%2,362
George Soros 2017-12-31 New Buy0.01%$193.73 - $227.15 $ 220.343%2,100
Joel Greenblatt 2017-12-31 Reduce -95.64%0.11%$193.73 - $227.15 $ 220.343%1,835
Vanguard Health Care Fund 2017-12-31 Sold Out 0.64%$193.73 - $227.15 $ 220.343%0
T Rowe Price Equity Income Fund 2017-09-30 Reduce -10.52%0.09%$191.56 - $205.63 $ 220.3411%840,000
Mario Gabelli 2017-09-30 Reduce -52.72%0.06%$191.56 - $205.63 $ 220.3411%47,316
Joel Greenblatt 2017-09-30 Add 214.05%0.08%$191.56 - $205.63 $ 220.3411%42,133
Robert Olstein 2017-09-30 Reduce -1.85%0.01%$191.56 - $205.63 $ 220.3411%26,600
Dodge & Cox 2017-09-30 Reduce -0.64%$191.56 - $205.63 $ 220.3411%7,730
Ken Fisher 2017-09-30 Add 17.94%$191.56 - $205.63 $ 220.3411%2,340
Vanguard Health Care Fund 2017-06-30 Add 53.40%0.22%$177.07 - $195.15 $ 220.3418%1,522,573
T Rowe Price Equity Income Fund 2017-06-30 Reduce -6.96%0.06%$177.07 - $195.15 $ 220.3418%938,800
Mario Gabelli 2017-06-30 Reduce -13.99%0.02%$177.07 - $195.15 $ 220.3418%100,076
Robert Olstein 2017-06-30 Reduce -24.93%0.21%$177.07 - $195.15 $ 220.3418%27,100
Joel Greenblatt 2017-06-30 New Buy0.04%$177.07 - $195.15 $ 220.3418%13,416
Dodge & Cox 2017-06-30 Reduce -11.89%$177.07 - $195.15 $ 220.3418%7,780
Ken Fisher 2017-06-30 Add 19.59%$177.07 - $195.15 $ 220.3418%1,984
T Rowe Price Equity Income Fund 2017-03-31 Add 2.54%0.02%$164.8 - $185.34 $ 220.3423%1,009,000
Vanguard Health Care Fund 2017-03-31 Reduce -4.77%0.02%$164.8 - $185.34 $ 220.3423%992,573
Mario Gabelli 2017-03-31 Reduce -1.88%$164.8 - $185.34 $ 220.3423%116,356
Dodge & Cox 2017-03-31 Reduce -36.15%$164.8 - $185.34 $ 220.3423%8,830
Ken Fisher 2017-03-31 Reduce -5.74%$164.8 - $185.34 $ 220.3423%1,659
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Becton, Dickinson and Co

SymbolPriceYieldDescription
BDXA.PFD58.340.00

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339112    SIC: 3841
Compare:NYSE:BAX, NAS:ILMN, XPAR:EI, NYSE:BCR, NYSE:MTD, OCSE:COLO B, NYSE:WAT, TSE:4543, NYSE:RMD, NAS:XRAY, TSE:7733, NYSE:COO, NAS:HOLX, XSWX:STMN, NYSE:STE, NYSE:WST, SZSE:002294, NYSE:HRC, NYSE:CMD, TSE:7747 » details
Traded in other countries:BOX.Germany, BDX.Switzerland, 0R19.UK,
Headquarter Location:USA
Becton, Dickinson and Co is a healthcare company. It manufacture and sales medical supplies, devices, laboratory equipment and diagnostic products. It operates in two segments BD Medical and BD Life Sciences.

Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. International revenue accounts for less than 50% of the company's business. With CareFusion, BD has entered into medical systems (such as infusion pumps and ventilators) as well as procedural solutions businesses. The Bard deal gives the company a presence in urology, vascular, and oncology.

Top Ranked Articles about Becton, Dickinson and Co

BD Launches Circulating Cell-Free DNA Blood Collection Tube for Cancer and Non-Invasive Prenatal Testing Applications
BD Completes Asset Divestitures to Merit Medical
FDA Approves New HPV Test that Detects and Identifies HPV Genotypes that put Women at High Risk for Cervical Cancer
BD to Present at Leerink Partners 7th Annual Global Healthcare Conference
Vanguard Health Care Fund's Largest Sales of the 4th Quarter The fund trimmed its UnitedHealth, Cigna, Eli Lilly holdings
The Vanguard Health Care Fund (Trades, Portfolio), which is managed by Jean Hynes, sold shares of the following stocks in the fourth quarter. Read more...
Comparable Historical Revenue Schedules Inclusive of C. R. Bard Posted to BD Website
BD Launches New Los Angeles County Program to Equip Patients with Essential Resources for Safe Sharps Disposal
9 Stocks Ken Fisher Continues to Buy The guru added to these positions in the past 2 quarters
Fisher Investments is a fee-only investment managment firm that serves institutional and private clients around the world. CEO and Chief Investment Officer Ken Fisher (Trades, Portfolio) invested in the following stocks in both the third and fourth quarters. Read more...
BD Board Declares Dividend
BD Announces Completion of Enrollment in the Lutonix™ 014 Drug Coated Balloon Below-The-Knee Trial

Ratios

vs
industry
vs
history
PE Ratio 168.20
BDX's PE Ratio is ranked lower than
99% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.24 vs. BDX: 168.20 )
Ranked among companies with meaningful PE Ratio only.
BDX' s PE Ratio Range Over the Past 10 Years
Min: 10.27  Med: 19.46 Max: 188
Current: 168.2
10.27
188
Forward PE Ratio 20.79
BDX's Forward PE Ratio is ranked higher than
70% of the 37 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 25.84 vs. BDX: 20.79 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 168.20
BDX's PE Ratio without NRI is ranked lower than
99% of the 123 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.22 vs. BDX: 168.20 )
Ranked among companies with meaningful PE Ratio without NRI only.
BDX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 13.02  Med: 20.98 Max: 188
Current: 168.2
13.02
188
Price-to-Owner-Earnings 57.53
BDX's Price-to-Owner-Earnings is ranked lower than
83% of the 83 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.60 vs. BDX: 57.53 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
BDX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 10.59  Med: 17.91 Max: 99.85
Current: 57.53
10.59
99.85
PB Ratio 2.76
BDX's PB Ratio is ranked higher than
57% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.21 vs. BDX: 2.76 )
Ranked among companies with meaningful PB Ratio only.
BDX' s PB Ratio Range Over the Past 10 Years
Min: 2.68  Med: 3.98 Max: 5.6
Current: 2.76
2.68
5.6
PS Ratio 4.05
BDX's PS Ratio is ranked lower than
57% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.22 vs. BDX: 4.05 )
Ranked among companies with meaningful PS Ratio only.
BDX' s PS Ratio Range Over the Past 10 Years
Min: 1.99  Med: 2.75 Max: 4.53
Current: 4.05
1.99
4.53
Price-to-Free-Cash-Flow 28.32
BDX's Price-to-Free-Cash-Flow is ranked lower than
55% of the 74 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 26.51 vs. BDX: 28.32 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BDX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 13.39  Med: 19.54 Max: 35.09
Current: 28.32
13.39
35.09
Price-to-Operating-Cash-Flow 19.52
BDX's Price-to-Operating-Cash-Flow is ranked higher than
55% of the 94 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 20.46 vs. BDX: 19.52 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BDX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 8.75  Med: 12.45 Max: 21.82
Current: 19.52
8.75
21.82
EV-to-EBIT 82.40
BDX's EV-to-EBIT is ranked lower than
96% of the 119 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.38 vs. BDX: 82.40 )
Ranked among companies with meaningful EV-to-EBIT only.
BDX' s EV-to-EBIT Range Over the Past 10 Years
Min: 9.7  Med: 15.2 Max: 80.3
Current: 82.4
9.7
80.3
EV-to-EBITDA 38.38
BDX's EV-to-EBITDA is ranked lower than
85% of the 136 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.18 vs. BDX: 38.38 )
Ranked among companies with meaningful EV-to-EBITDA only.
BDX' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.5  Med: 11.4 Max: 37.4
Current: 38.38
7.5
37.4
EV-to-Revenue 6.55
BDX's EV-to-Revenue is ranked lower than
75% of the 195 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.26 vs. BDX: 6.55 )
Ranked among companies with meaningful EV-to-Revenue only.
BDX' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.2  Med: 2.9 Max: 6.4
Current: 6.55
2.2
6.4
PEG Ratio 46.72
BDX's PEG Ratio is ranked lower than
99% of the 67 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.63 vs. BDX: 46.72 )
Ranked among companies with meaningful PEG Ratio only.
BDX' s PEG Ratio Range Over the Past 10 Years
Min: 0.92  Med: 1.87 Max: 60.84
Current: 46.72
0.92
60.84
Shiller PE Ratio 41.33
BDX's Shiller PE Ratio is ranked higher than
54% of the 52 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 41.96 vs. BDX: 41.33 )
Ranked among companies with meaningful Shiller PE Ratio only.
BDX' s Shiller PE Ratio Range Over the Past 10 Years
Min: 17.07  Med: 24.9 Max: 46.21
Current: 41.33
17.07
46.21
Current Ratio 1.54
BDX's Current Ratio is ranked lower than
78% of the 200 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.42 vs. BDX: 1.54 )
Ranked among companies with meaningful Current Ratio only.
BDX' s Current Ratio Range Over the Past 10 Years
Min: 1.14  Med: 1.92 Max: 5.82
Current: 1.54
1.14
5.82
Quick Ratio 0.93
BDX's Quick Ratio is ranked lower than
80% of the 200 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.72 vs. BDX: 0.93 )
Ranked among companies with meaningful Quick Ratio only.
BDX' s Quick Ratio Range Over the Past 10 Years
Min: 0.7  Med: 1.24 Max: 5.1
Current: 0.93
0.7
5.1
Days Inventory 118.14
BDX's Days Inventory is ranked higher than
56% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 124.42 vs. BDX: 118.14 )
Ranked among companies with meaningful Days Inventory only.
BDX' s Days Inventory Range Over the Past 10 Years
Min: 103.39  Med: 120.58 Max: 127.55
Current: 118.14
103.39
127.55
Days Sales Outstanding 59.59
BDX's Days Sales Outstanding is ranked higher than
52% of the 162 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 60.68 vs. BDX: 59.59 )
Ranked among companies with meaningful Days Sales Outstanding only.
BDX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.31  Med: 56.82 Max: 61.75
Current: 59.59
47.31
61.75
Days Payable 46.84
BDX's Days Payable is ranked lower than
54% of the 147 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 54.66 vs. BDX: 46.84 )
Ranked among companies with meaningful Days Payable only.
BDX' s Days Payable Range Over the Past 10 Years
Min: 27.63  Med: 34.33 Max: 47.29
Current: 46.84
27.63
47.29

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 1.33
BDX's Dividend Yield % is ranked higher than
67% of the 172 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.23 vs. BDX: 1.33 )
Ranked among companies with meaningful Dividend Yield % only.
BDX' s Dividend Yield % Range Over the Past 10 Years
Min: 1.12  Med: 1.77 Max: 2.44
Current: 1.33
1.12
2.44
Dividend Payout Ratio 2.33
BDX's Dividend Payout Ratio is ranked lower than
99% of the 100 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.29 vs. BDX: 2.33 )
Ranked among companies with meaningful Dividend Payout Ratio only.
BDX' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.26  Med: 0.35 Max: 0.72
Current: 2.33
0.26
0.72
3-Year Dividend Growth Rate 10.20
BDX's 3-Year Dividend Growth Rate is ranked higher than
60% of the 62 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.00 vs. BDX: 10.20 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
BDX' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 2.6  Med: 11 Max: 29.1
Current: 10.2
2.6
29.1
Forward Dividend Yield % 1.36
BDX's Forward Dividend Yield % is ranked higher than
54% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.36 vs. BDX: 1.36 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 2.17
BDX's 5-Year Yield-on-Cost % is ranked higher than
70% of the 203 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.44 vs. BDX: 2.17 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
BDX' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.81  Med: 2.86 Max: 3.95
Current: 2.17
1.81
3.95
3-Year Average Share Buyback Ratio -5.90
BDX's 3-Year Average Share Buyback Ratio is ranked lower than
55% of the 137 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -4.40 vs. BDX: -5.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BDX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -5.9  Med: 1.2 Max: 6.1
Current: -5.9
-5.9
6.1

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.65
BDX's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
69% of the 81 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.29 vs. BDX: 1.65 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BDX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.99  Med: 1.59 Max: 3.81
Current: 1.65
0.99
3.81
Price-to-Intrinsic-Value-DCF (Earnings Based) 15.72
BDX's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
96% of the 23 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.14 vs. BDX: 15.72 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
BDX' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.68  Med: 1.34 Max: 15.27
Current: 15.72
0.68
15.27
Price-to-Median-PS-Value 1.47
BDX's Price-to-Median-PS-Value is ranked lower than
70% of the 165 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.11 vs. BDX: 1.47 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BDX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.4  Med: 0.86 Max: 1.43
Current: 1.47
0.4
1.43
Earnings Yield (Greenblatt) % 1.21
BDX's Earnings Yield (Greenblatt) % is ranked lower than
56% of the 203 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.51 vs. BDX: 1.21 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BDX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.2  Med: 6.6 Max: 10.4
Current: 1.21
1.2
10.4
Forward Rate of Return (Yacktman) % 6.02
BDX's Forward Rate of Return (Yacktman) % is ranked lower than
63% of the 98 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.68 vs. BDX: 6.02 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BDX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 5  Med: 13.6 Max: 19.6
Current: 6.02
5
19.6

More Statistics

Revenue (TTM) (Mil) $12,250.00
EPS (TTM) $ 1.31
Beta1.08
Short Percentage of Float2.19%
52-Week Range $175.66 - 248.39
Shares Outstanding (Mil)266.24

Analyst Estimate

Sep18 Sep19
Revenue (Mil $) 14,814 16,284
EBIT (Mil $) 2,867 3,662
EBITDA (Mil $) 4,246 5,198
EPS ($) 10.66 12.08
EPS without NRI ($) 10.66 12.08
EPS Growth Rate
(Future 3Y To 5Y Estimate)
11.47%
Dividends per Share ($) 3.20 3.44

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}